There are results due from Gradalis and Calimmune. I would not...

There are results due from Gradalis and Calimmune. I would not expect that the rise has been due to either of these. This would be considered insider trading. It happens, but probably not to this extent.

Personally, I believe it is simply down to US exposure (thanks Karmaswimswami). If the US RNAi companies are at fair value, then we still have a long way to go. I think we are worth more than Arrowhead, currently at $1b. Sure they now have safety trials done but ddRNAi as a whole has much more safety data, through BLT's HIV PI with the City of Hope, Calimmune and Gradalis. Over 150 patients.